Japanese pharma firm Daiichi Sankyo Company has announced that it has decided to discontinue development of nafamostat inhalation formulation (DS-2319) for treatment of the novel coronavirus infectious disease (COVID-19).
Daiichi Sankyo Company, Limited announced that it has initiated in Japan a first-in-human phase 1 trial for nafamostat inhalation formulation (DS-2319), which is being developed as a potential medicine for the treatment of the novel coronavirus infectious disease (Covid-19).
Chong Kun Dang’s anticoagulant and acute pancreatitis treatment Nafabeltan (nafamostat) is to undergo a clinical phase two trial in Russia repositioned as a potential COVID-19 treatment, CKD said Tuesday.
The University of Tokyo, RIKEN, Nichi-Iko Pharmaceutical Co., Ltd. and Daiichi Sankyo Company, Limited have reached a basic agreement on collaborative R&D on a nafamostat inhalation formulation for the treatment of novel coronavirus infection (COVID-19).
Sun Pharmaceutical Industries has secured approval from the Drugs Controller General of India (DCGI) to conduct a clinical trial of pancreatitis drug, Nafamostat Mesilate, to treat Covid-19 patients in the country.
Scientists have found that nafamostat, at very low concentrations, suppresses a protein that that the novel coronavirus uses to enter human lung cells
research team at the Institut Pasteur Korea have identified a drug that appears to be more effective in treating COVID-19 than Gilead’s remdesivir. The drug is called Nafamostat, which is used to treat pancreatic cancer, and it is a potent antiviral inhibitor. This was proven to be the most effective out of 24 therapeutic candidates, with these drugs being tested in an experiment with a Vero cell culture.
The University of Tokyo said on May 8 that it has initiated a clinical study investigating the combination use of the antiviral Avigan (favipiravir) and the pancreatitis drug Futhan (nafamostat) for the treatment of patients with COVID-19 pneumonia. The multicenter,…
SAN DIEGO--(BUSINESS WIRE)--Ensysce Biosciences Inc. announced that it is exploring the opportunity to initiate a clinical trial of oral Nafamostat, an ingredient from its opioid overdose protection platform, as a treatment for COVID-19. The goal is to evaluate if nafamostat mesylate (Nafamostat), a synthetic protease inhibitor will be effective in preventing or reducing the lethal outcome of COVID-19 infection.